Publications by authors named "Richard Vile"

Claim this Profile
T
T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy.
Thanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, Olivia Liseth, Jill Thompson, Richard G Vile

Mol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.
Alexa Veliz Rios, Muriel Metko, Jason Tonne, Jill Thompson, Benjamin Kendall, Richard Vile

Mol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.
Richard G Vile

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.
Elizabeth Appleton, E Antonio Chiocca, Guy Ungerechts, Alan Melcher, Richard Vile

Lancet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment.
Natalie M Elliott, Benjamin L Kendall, Souyma Dutta, Daipayan Sarkar, John W Vant, Richard Vile

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.
Victoria Roulstone, Joan Kyula-Currie, James Wright, Emmanuel C Patin, Isaac Dean, Richard Vile

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.
Benjamin L Kendall, Richard G Vile

Immunotherapy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.
Victoria Roulstone, Joan Kyula-Currie, James Wright, Emmanuel C Patin, Isaac Dean, Richard Vile

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunodominant antiviral T cell responses outcompete immuno-subdominant antitumor responses to reduce the efficacy of oncolytic viroimmunotherapy.
Richard Vile, Benjamin Kendall, Olivia Liseth, Thanich Sangsuwannukul, Natalie Elliott

Res Sq· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOBEC3B expression in 293T viral producer cells drives mutations in chimeric antigen receptors and reduces CAR T cell efficacy.
Jack Swanson, Jason Tonne, Thanich Sangsuwannukul, Jill Thompson, Benjamin Kendall, Richard Vile

Mol Ther Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.
Richard Vile, Jose Pulido, Alex Chen, Benjamin Kendall, Jason Tonne

Res Sq· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.
Muriel Metko, Jason Tonne, Alexa Veliz Rios, Jill Thompson, Haley Mudrick, Richard G Vile

Vaccines (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification.
Jason M Tonne, Karol Budzik, Talia Fernandez Carrasco, Landon Ebbert, Jill Thompson, Richard G Vile

Mol Ther Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
Mason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Richard Vile

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
David R Miley, Cynthia M Andrews-Pfannkoch, Jose S Pulido, Samantha A Erickson, Richard G Vile

Melanoma Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, Adam J Weisbrod, Carrie A Strand, Richard G Vile

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimerization of the Anti-Viral CD8 T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy.
Richard Vile, Mason Webb, Jacob van Vloten, Laura Evgin, Thanich Sangsuwannukul

Res Sq· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
Bolni Marius Nagalo, Yumei Zhou, Emilien J Loeuillard, Chelsae Dumbauld, Oumar Barro, Richard Vile

Hepatology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression.
Zachariah P Tritz, Katayoun Ayasoufi, Delaney M Wolf, Carley A Owens, Courtney S Malo, Richard G Vile

Cancer Immunol Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic viruses: Narcissistic or altruistic arsonists?
Luke Kendall, Richard G Vile

Mol Ther Oncolytics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.
Mason J Webb, Timothy Kottke, Benjamin L Kendall, Jack Swanson, Chisom Uzendu, Richard Vile

Mol Ther Oncolytics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.
Mason J Webb, Ugur Sener, Richard G Vile

Pharmaceuticals (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells.
Marco Künzli, Stephen D O'Flanagan, Madeleine LaRue, Poulami Talukder, Thamotharampillai Dileepan, Richard Vile

Sci Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Adel Samson, Emma J West, Jonathan Carmichael, Karen J Scott, Samantha Turnbull, Richard G Vile

Cancer Immunol Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors.
Matthew R Schuelke, Justin H Gundelach, Matt Coffey, Emma West, Karen Scott, Richard G Vile

Neurooncol Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis